All In Biotech

Drug Trial Radar · NCT07039045

A Study of [14C]-LY4065967 in Healthy Participants

A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jun 23, 2025

Primary completion

Aug 16, 2025

Study completion Aug 16, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.

Conditions

  • Healthy

Interventions

  • LY4065967Drug

    Oral dose

  • [14C]-LY4065967 OralRadiation

    Oral dose

  • [14C]-LY4065967 IVRadiation

    IV dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percentage of Total Radioactive Dose in Urine and Fecal ExcretionTime frame: Baseline through Study Completion (21 days)
  2. Part 2: Plasma Area Under the Concentration-time Curve from Zero to Infinity (AUC(0-ꝏ)) for LY4065967Time frame: Baseline through Study Completion (9 Days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.